CG Oncology Announces Proposed Public Offering

Company Overview - CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [5]. Proposed Offering - CG Oncology has filed a registration statement on Form S-1 with the SEC for a proposed underwritten public offering of 7,300,000 shares of its common stock [1]. - An existing stockholder intends to offer and sell 700,000 shares of CG Oncology's common stock in the proposed offering [1]. - The company will not receive proceeds from the sale of shares by the selling stockholder [1]. - CG Oncology plans to grant underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions [1]. - The public offering price has not yet been determined, and the offering is subject to market and other conditions [1]. Underwriters - Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, TD Cowen, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [2]. - LifeSci Capital LLC is serving as the lead manager for the offering [2]. Registration Statement - A registration statement relating to these securities has been filed with the SEC but has not yet become effective [3]. - The proposed offering will be made only by means of a prospectus, which will be available from the underwriters when ready [3].